Abstract: OBJECTIVE To evaluate efficacy of probucol against atherosclerosi by systematic review. METHODS Relevant RCTs were identified by searching electronic databases including Medline, Embase, Cochrane Library, VIP, CNKI, Wanfang data, CBM. It was collected by randomized controll trials (RCT) to compare probucol with placebo and no treatment or other convention. The methodological quality of extracted data were assessed, meta-analysis was performed using RevMan 5.3 software. RESULTS A total of 20 studies, involving 1 314 patients were included. Results of meta-analysis showed that lumenarea WMD 0.80, 95%CI(0.41-1.20), P<0.000 01, inimal lumen diameter WMD 0.24, 95%CI(0.17-0.30), P<0.000 01, incidence of restenosis RR=0.66, 95% CI(0.56-0.78), P<0.000 01, degree of restenosis WMD=-11. 20, 95% CI(-17. 02-5.38), P=0.000 02, adverse events of atherosclerosis RR=0.57, 95% CI(0.48-0.67), P<0.000 01 of probucol group were better than those of control group, there was statistical significance. CONCLUSION Probucol can decrease the incidence of restenosis and atherosclerosis related events and preserve minimal lumen diameter and lumen area significantly.